Quantum Leap Healthcare Collaborative
search
Agents & Results

Agent Information

The I-SPY Program is committed to open science, through timely publication and release of results, and ultimately data, from all arms of our trials.
Close
Close
I-SPY Trial Manuscript
Close
Close
Close
Close
I-SPY People
Close
Close
<- Back to All Agents

ganitumab

Trade Name:
AMG-479
Company:
Amgen
Status:
Stopped for Futility
Agent Chaperone(s):
Douglas YeeClaudine Isaacs
Treatment Protocol:
Ganitumab is a fully human monoclonal antibody (IgG1). Ganitumab was adminstered at 12 mg/kg by intravenous infusion every 2 weeks (q2w) with Paclitaxel at 80 mg/m2 once a week(q1w) for 12 weeks. This regimen was followed by AC (q2w or q3w) for 4 weeks.
Date Entered I-SPY:
July 9, 2012
Date Left I-SPY:
February 10, 2015
No. Participants in Arm:
122
Graduating Subtypes:
Agent Description:

Ganitumab (AMG-479) is a fully human monoclonal IgG 1 antibody that binds insulin-like growth factor 1 receptor (IGF-I receptor) and is being evaluated in clinical studies as monotherapy and in combination with other agents. The IGF system ganitumab targets has been implicated in the risk of cancer in recent years, including evidence from epidemiological data, research in cancer models and knowledge of the downstream signaling pathways Ras/Raf/extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and lipid kinase phosphatidylinositol 3-kinase (PI3K)/AKT, networks which are involved in cell proliferation and survival. As a result, various means of targeting the IGF-I receptor are being explored.

Notes:
Final pCR Probabilities:
Primary Manuscript:
, 
. 
 
: 
, 
. 
abstractpdfdoi link

The I-SPY Trials

Sponsored by Quantum Leap Healthcare Collaborative™, a 501C(3) charitable organization accelerating the union of high-impact clinical research and patient care to improve and save lives.

 
Quick Links:
Media CenterCareersInvestigator Login
© 2019  Quantum Leap Healthcare Collaborative